161 related articles for article (PubMed ID: 35352023)
1. miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.
El Bezawy R; Percio S; Ciniselli CM; De Cesare M; Colella G; Dugo M; Veneroni S; Doldi V; Martini S; Baratti D; Kusamura S; Verderio P; Deraco M; Gandellini P; Zaffaroni N; Zuco V
Cancer Gene Ther; 2022 Oct; 29(10):1394-1404. PubMed ID: 35352023
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
[TBL] [Abstract][Full Text] [Related]
3. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.
Cimino-Reale G; Gandellini P; Santambrogio F; Recagni M; Zaffaroni N; Folini M
J Hematol Oncol; 2017 Jul; 10(1):140. PubMed ID: 28716051
[TBL] [Abstract][Full Text] [Related]
4. Reduced miR-550a-3p leads to breast cancer initiation, growth, and metastasis by increasing levels of ERK1 and 2.
Ho JY; Hsu RJ; Wu CH; Liao GS; Gao HW; Wang TH; Yu CP
Oncotarget; 2016 Aug; 7(33):53853-53868. PubMed ID: 27462780
[TBL] [Abstract][Full Text] [Related]
5. MiR-550a-3p promotes non-small cell lung cancer cell proliferation and metastasis through down-regulating TIMP2.
Yang JZ; Bian L; Hou JG; Wang HY
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(13):4156-4165. PubMed ID: 30024604
[TBL] [Abstract][Full Text] [Related]
6. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
Belfiore A; Busico A; Bozzi F; Brich S; Dallera E; Conca E; Capone I; Gloghini A; Volpi CC; Cabras AD; Pilotti S; Baratti D; Guaglio M; Deraco M; Kusamura S; Perrone F
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752449
[TBL] [Abstract][Full Text] [Related]
7. LINC00261/microRNA-550a-3p/SDPR axis affects the biological characteristics of breast cancer stem cells.
Li Y; Wu C
IUBMB Life; 2021 Jan; 73(1):188-201. PubMed ID: 33274565
[TBL] [Abstract][Full Text] [Related]
8. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP.
Choe MH; Yoon Y; Kim J; Hwang SG; Han YH; Kim JS
Cell Death Dis; 2018 May; 9(6):640. PubMed ID: 29844307
[TBL] [Abstract][Full Text] [Related]
9. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
10. KCNQ1OT1 facilitates progression of non-small-cell lung carcinoma via modulating miRNA-27b-3p/HSP90AA1 axis.
Dong Z; Yang P; Qiu X; Liang S; Guan B; Yang H; Li F; Sun L; Liu H; Zou G; Zhao K
J Cell Physiol; 2019 Jul; 234(7):11304-11314. PubMed ID: 30471108
[TBL] [Abstract][Full Text] [Related]
11. Mir-421 and mir-550a-1 are potential prognostic markers in esophageal adenocarcinoma.
Ji Y; Wang L; Chang G; Yan J; Dai L; Ji Z; Liu J; He M; Xu H; Zhang L
Biol Direct; 2023 Feb; 18(1):5. PubMed ID: 36829221
[TBL] [Abstract][Full Text] [Related]
12. miR-142-3p Suppresses Invasion and Adhesion of Mesothelioma Cells by Downregulating ITGAV.
Endo I; Amatya VJ; Kushitani K; Nakagiri T; Aoe K; Takeshima Y
Pathobiology; 2023; 90(4):270-280. PubMed ID: 36724751
[TBL] [Abstract][Full Text] [Related]
13. Interplay between cancer cells and M2 macrophages is necessary for miR-550a-3-5p down-regulation-mediated HPV-positive OSCC progression.
Cao MX; Zhang WL; Yu XH; Wu JS; Qiao XW; Huang MC; Wang K; Wu JB; Tang YJ; Jiang J; Liang XH; Tang YL
J Exp Clin Cancer Res; 2020 Jun; 39(1):102. PubMed ID: 32493454
[TBL] [Abstract][Full Text] [Related]
14. A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma.
Oliveto S; Alfieri R; Miluzio A; Scagliola A; Secli RS; Gasparini P; Grosso S; Cascione L; Mutti L; Biffo S
Cancer Res; 2018 Oct; 78(20):5741-5753. PubMed ID: 30072395
[TBL] [Abstract][Full Text] [Related]
15. RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis.
Toda H; Seki N; Kurozumi S; Shinden Y; Yamada Y; Nohata N; Moriya S; Idichi T; Maemura K; Fujii T; Horiguchi J; Kijima Y; Natsugoe S
Mol Oncol; 2020 Feb; 14(2):426-446. PubMed ID: 31755218
[TBL] [Abstract][Full Text] [Related]
16. HSP90: A Novel Target Gene of miRNA-628-3p in A549 Cells.
Pan J; Jiang F; Zhou J; Wu D; Sheng Z; Li M
Biomed Res Int; 2018; 2018():4149707. PubMed ID: 29888262
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
18. miR-550a-5p promotes the proliferation and migration of hepatocellular carcinoma by targeting GNE via the Wnt/β-catenin signaling pathway.
Li CM; Wu W; Zhu Z; Lu PL; Gong JP; Ma R
Neoplasma; 2022 Dec; 69(6):1359-1372. PubMed ID: 36353937
[TBL] [Abstract][Full Text] [Related]
19. MiR-550a-3p restores damaged vascular smooth muscle cells by inhibiting thrombomodulin in an in vitro atherosclerosis model.
Chen S; Zhang L; Feng B; Wang W; Liu D; Zhao X; Yu C; Wang X; Gao Y
Eur J Histochem; 2022 Jul; 66(3):. PubMed ID: 35855629
[TBL] [Abstract][Full Text] [Related]
20. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
Williams M; Kirschner MB; Cheng YY; Hanh J; Weiss J; Mugridge N; Wright CM; Linton A; Kao SC; Edelman JJ; Vallely MP; McCaughan BC; Cooper W; Klebe S; Lin RC; Brahmbhatt H; MacDiarmid J; van Zandwijk N; Reid G
Oncotarget; 2015 Sep; 6(27):23480-95. PubMed ID: 26125439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
